Beta

Spending
Congress
Stocks
Lobbying

Spending
Congress
Stocks
Lobbying

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Congress
Stocks
Lobbying

LD-2 disclosure · 2nd Quarter - Termination

KABAFUSION

via BROWNSTEIN HYATT FARBER SCHRECK, LLP

2nd Quarter (Apr 1 - June 30) · 2021Posted Jul 18, 2021Filing document ↗LDA record ↗

Income$20Kfee reported

Client

Name: KABAFUSION
Description: Infusion therapy
Location: California · United States of America

Registrant

Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Description: Law firm
Location: Washington, District of Columbia, United States of America

Lobbying activities

1 issue

Health Issues
Issues related to infusion therapy
LobbyistsR. JAMES NICHOLSON · ARACELI GUTIERREZ · mr EDWARD RANDALL ROYCE
TargetedBureau of Indian Affairs (BIA)

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.

KABAFUSION — Lobbying — Receipts Report